Reactivity of a new Pan-B monoclonal antibody (MA6) against human leukaemias.
The reactivity of a new Pan-B monoclonal antibody, MA6, against 69 cases of ALL, three plasmacytoma, 10 AML and five CML was evaluated. The antibody reacted positively against five of the 11 cases of U-ALL, 15 of the 26 C-ALL and all the cases of Pre B-ALL (one), B-ALL (one), B-CLL (12) and HCL (two). The MA6 did not react against the 16 cases of T-ALL, three plasmacytoma, 10 AML and five CML. The antibody has a broader spectrum of B-cell reactivity than CD9 and CD20 but is similar to the Pan-B antibody, CD19. MA6 appears to react against some of the very immature B cells and is therefore potentially useful, in conjunction with other antibodies such as CD9 and CD19, to confirm the B-lineage of some cases of U-ALL. The difference in the spectrum of reactivity against B-cell malignancies between MA6 and the other CDw40 antibody, G28-5, confirms their difference in antigenic specificity.
Chen
Z
Z
Institute of Haematology, Chinese Academy of Medical Sciences, Tianjin, People's Republic of China.
Tang
M H
MH
Chan
K H
KH
Ng
M H
MH
Liang
R
R
D000911:Antibodies, Monoclonal / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D005455:Fluorescent Antibody Technique; D006801:Humans; D007938:Leukemia / Q000276:immunology*
D000911:Antibodies, Monoclonal